ProMIS Neurosciences Inc. reports clinical-stage biotechnology developments around antibody therapeutics and vaccines that target toxic misfolded proteins in neurodegenerative diseases. Company news centers on PMN310, its lead humanized monoclonal antibody for Alzheimer’s disease, the PRECISE-AD clinical program, FDA Fast Track designation, biomarker research involving plasma pTau, and scientific publications or conference presentations tied to Alzheimer’s disease, ALS, and Parkinson’s disease.
Updates also cover operating and financial results, governance matters, shareholder votes, capital-structure actions, and investor conference participation. The company’s research disclosures emphasize its proprietary discovery platform and selective targeting of disease-specific toxic protein species rather than broader amyloid plaque binding.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ProMIS Neurosciences (TSX: PMN, Nasdaq: PMN) recently showcased preclinical data supporting its Aβ vaccine candidate aimed at preventing Alzheimer’s disease (AD) progression. The findings were presented at the AAN 2023 Annual Meeting, highlighting the vaccine’s potential advantages over traditional antibody treatments, including sustained efficacy, fewer required doses, and reduced risks of inflammatory responses. The computationally designed vaccine targets misfolded Aβ oligomers—key drivers of AD—showing promising immune responses in mouse models. No adverse T helper responses were observed, and the vaccine selectively activated antibodies against toxic oligomers, potentially minimizing risks associated with plaque-binding antibodies. ProMIS’s focus remains on developing an effective AD vaccine to combat neurodegenerative diseases.
Summary not available.
ProMIS Neurosciences Inc. (TSX: PMN; Nasdaq: PMN) announced the submission of an Investigational New Drug (IND) application to the FDA for PMN310, targeting Alzheimer’s disease (AD). This is a significant milestone in advancing PMN310 towards clinical trials, offering potential new treatment options for AD patients. PMN310 selectively targets toxic oligomers of amyloid-beta, a key factor in AD pathology, showing strong binding to these harmful proteins in preclinical studies. The company anticipates transitioning to a clinical-stage entity pending regulatory approval. Management emphasizes the antibody's potential for a differentiated safety profile compared to existing treatments, which often bind to non-targeted plaques, potentially minimizing associated risks.
ProMIS Neurosciences (TSX: PMN) has announced promising results for its lead candidate, PMN310, which targets toxic oligomers linked to Alzheimer’s disease (AD). In a recent presentation at the AD/PD 2023 conference, new preclinical data showed PMN310 selectively binds to these harmful oligomers, differentiating it from other amyloid-beta-directed antibodies. This selectivity may reduce the risk of side effects commonly associated with plaque-binding therapies. ProMIS plans to submit an IND application in the coming weeks for clinical development of PMN310, aiming to advance its treatment options for patients suffering from AD.
ProMIS Neurosciences Inc. (TSX: PMN, Nasdaq: PMN), a biotechnology company specializing in antibody therapeutics for neurodegenerative diseases, announced presentations at the upcoming American Academy of Neurology Annual Meeting, scheduled for April 22-27, 2023, in Boston, MA. The event will feature an oral presentation and two poster presentations on their drug development pipeline, including lead candidate PMN310 for Alzheimer's disease, a new Alzheimer's vaccine, and potential therapeutic target RACK1 for ALS. Dr. Johanne Kaplan will present on the rational design of vaccines and antibody protection against amyloid-beta oligomers.